MedTrace Logo

Practice Variation on Antithrombotics in COVID-19

NCT04998799 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 435

Last updated 2021-11-24

No results posted yet for this study

Summary

Evidence suggests coronavirus disease 2019 (COVID-19) is associated with an increased incidence of thromboembolic manifestations. Various guidelines on managing antithrombotics in COVID-19 either provided conflicting guidance or unclear recommendations for post-discharge thromboprophylaxis.

The investigators aim to collect the current practices in India among physicians on antithrombotic therapy for hospitalised patients with COVID-19 and after discharge from the hospital.

Conditions

Interventions

BEHAVIORAL

Current clinical practices of participating physicians

Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge

Sponsors & Collaborators

  • NMC Specialty Hospital

    lead OTHER

Principal Investigators

  • Prashant Nasa, MD EDICM · NMC Specialty Hospital, Dubai, UAE

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2021-10-30
Completion
2021-11-10

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04998799 on ClinicalTrials.gov